Descripción del proyecto
Un esfuerzo multidisciplinario coordinado para desarrollar un tratamiento contra los brotes de coronavirus
La respuesta a la pandemia de SARS-CoV-2 y los futuros brotes de coronavirus requieren un esfuerzo organizado y el trasvase rápido de los descubrimientos científicos a los socios industriales. El proyecto financiado con fondos europeos MAD-CoV 2 ha reunido un equipo multidisciplinario de investigadores y socios industriales innovadores para estudiar las infecciones víricas en las células del huésped y traducir rápidamente los conocimientos en medicamentos nuevos y en medidas de salud pública. La enzima conversora de la angiotensina 2 (ECA2) constituye una prometedora diana farmacológica para el tratamiento de las enfermedades cardiovasculares y también actúa como punto de entrada celular para algunos coronavirus. Los objetivos de MAD-CoV 2 son descubrir el papel de la ECA2 en la replicación vírica y la patogenia de la COVID-19, y traducir estos conocimientos en tratamientos nuevos para luchar contra los brotes de coronavirus. Por otra parte, el proyecto desarrollará estrategias nuevas para crear antivirales contra el SARS-CoV-2 y otras enfermedades víricas emergentes.
Objetivo
The SARS-CoV-2 pandemic has become an unprecedented burden to public health, our civil societies and the global economy. To provide frontline therapies for COVID-19 and future corona virus outbreaks requires a concerted effort of different disciplines, technologies, high security labs, and rapid translation of scientific findings to highly innovative and “hungry” SME partners. For the MAD-CoV-2 project we have assembled a multidisciplinary team of world-leading researchers and innovative industry partners to unlock the Achille’s heels of the virus infections in host cells and rapidly translate such knowledge into disruptive new medicines and public health measures. Our team members have been on the ground of the first SARS and Ebola outbreaks, head containment facilities to study highly infectious viruses, are world-leading in engineering human tissues, developed breakthrough technologies that allow us to find host factors for viral infections at unmatched speed and resolution, and discovered ACE2 and made the first in vivo link between ACE2, SARS, and lung injury, leading to rational drug development which is imminent to be tested in European COVID-19 patients. ACE2 is also the key receptor for SARS-CoV-2 Spike protein and has got centre stage for novel therapies and a fundamental understanding of COVID-19. The aims of MAD-CoV-2 are 1. to engineer human tissues to test novel therapies and vaccines; 2. to provide critical evidence on the role of clinical grade ACE2 in viral replication and COVID-19 pathogenesis; 3. to perform high-throughput screens to genetically map, at a single amino acid resolution, essential host factor that are critical for SARS-CoV-2 replication; and 4. to rapidly translate this knowledge into novel therapies to fight the current and, importantly, future corona virus outbreaks.
Our data and unique tissue reagents will be made available to the entire community for drug testing and development, supporting all other efforts.
Ámbito científico
- medical and health sciencesbasic medicinepharmacology and pharmacydrug discovery
- natural sciencesbiological sciencesmicrobiologyvirology
- medical and health scienceshealth sciencesinfectious diseasesRNA virusesebola
- medical and health scienceshealth sciencesinfectious diseasesRNA virusescoronaviruses
- medical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsantivirals
Palabras clave
Programa(s)
Tema(s)
Convocatoria de propuestas
H2020-JTI-IMI2-2020-21-single-stage
Consulte otros proyectos de esta convocatoriaRégimen de financiación
RIA - Research and Innovation actionCoordinador
75189 Uppsala
Suecia